서울대학교 생물정보학 협동과정 주최로 세미나를 아래와 같이 열고자 하오니 많은 참여 바랍니다.

세미나는 Zoom을 통한 온라인 강의로 예정되어 있으며 강의에 참여하고자 하시는 분께서는 아래의 링크로 참여 부탁드리겠습니다.

*줌으로 참석하기 위해서는 "참석자로 회의 참가" --> 이름, 성, 이메일 주소, 이메일 주소 확인을 입력하시고 등록하시면 회의 참석이 가능합니다.

일시: 2022년 9월 22일 목요일 오전 11시

연사: 신재국 교수님 (인제대학교)

Clinical Implementation for Personalized Precision Pharmacotherapy based on

Pharmacogenomics: Status and Perspectives

Jae-Gook Shin, MD, PhD

Dept. of Pharmacology and Pharmacogenomics Research Center, Dept. of Clinical

Pharmacology, Inje University College of Medicine, Center for Personalized Precision

Medicine of Tuberculosis (cPMTb) supported by National Research Foundation of

Korea/ Ministry of Science and ICT, Busan, Korea

It is well known dogma of pharmacology that therapeutic drug response varies among the individual　patients from the same therapeutic dose regimen. The drug response variation caused by many factors　of individual subjects such as pharmacogenotype, drug interaction, age, body weight renal/hepatic　dysfunction, ethnicity etc. Pharmacogenotypes are considered to be a good predictor of individual　drug responses for the personalized pharmacotherapy in a given individual patient. Although it is still　limited, the pharmacogenetic tests became a routine practice for the personalized pharmacotherapy,　and several pharmacogenomics biomarkers listed in the drug label are already allowed for genotype　based pharmacotherapy in clinical practice with insurance coverage for reimbursement. Therefore,　personalized precision medicine based on an individual pharmacogenotypes has been established in　the clinical practice, at least in some therapeutic areas including the treatment of cancer,　cardiovascular diseases, psychiatric drugs and prevention of serious adverse drug reactions.

The genotype guided personalized dose regimen is available to be predicted from the clinical

documents collected from clinical trials/ studies done in an individual with specific

pharmacogenotypes. However, this approach may not be available for such edge population patients　who are exposed to many other clinical conditions such as combined effect of genetic and non-genetic　effects, i.e. genetic + drug interactions + renal dysfunction + old age. Therefore, it is asked to have　additional solutions to predict the personalized precision dosing of an individual patients exposed to　diverse clinical situation in real world clinical practice.

The presentation will introduce the personalized pharmacotherapy based on pharmacogenomics

and also model informed precision dosing as a potential tool for precision medicine of real world edge　patient population.